Literature DB >> 18172327

Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women.

Marc J Gunter1, Donald R Hoover, Herbert Yu, Sylvia Wassertheil-Smoller, Thomas E Rohan, JoAnn E Manson, Barbara V Howard, Judith Wylie-Rosett, Garnet L Anderson, Gloria Y F Ho, Robert C Kaplan, Jixin Li, Xiaonan Xue, Tiffany G Harris, Robert D Burk, Howard D Strickler.   

Abstract

Obesity is a risk factor for colorectal cancer, and hyperinsulinemia, a common condition in obese patients, may underlie this relationship. Insulin, in addition to its metabolic effects, has promitotic and antiapoptotic activity that may be tumorigenic. Insulin-like growth factor (IGF)-I, a related hormone, shares sequence homology with insulin, and has even stronger mitogenic effects. However, few prospective colorectal cancer studies directly measured fasting insulin, and none evaluated free IGF-I, or endogenous estradiol, a potential cofactor in postmenopausal women. Therefore, we conducted a case-cohort investigation of colorectal cancer among nondiabetic subjects enrolled in the Women's Health Initiative Observational Study, a prospective cohort of 93,676 postmenopausal women. Fasting baseline serum specimens from all incident colorectal cancer cases (n = 438) and a random subcohort (n = 816) of Women's Health Initiative Observational Study subjects were tested for insulin, glucose, total IGF-I, free IGF-I, IGF binding protein-3, and estradiol. Comparing extreme quartiles, insulin [hazard ratio (HR)(q4-q1), 1.73; 95% confidence interval (CI), 1.16-2.57; P(trend) = 0.005], waist circumference (HR(q4-q1), 1.82; 95% CI, 1.22-2.70; P(trend) = 0.001), and free IGF-I (HR(q4-q1), 1.35; 95% CI, 0.92-1.98; P(trend) = 0.05) were each associated with colorectal cancer incidence in multivariate models. However, these associations each became nonsignificant when adjusted for one another. Endogenous estradiol levels, in contrast, were positively associated with risk of colorectal cancer (HR comparing high versus low levels, 1.53; 95% CI, 1.05-2.22), even after control for insulin, free IGF-I, and waist circumference. These data suggest the existence of at least two independent biological pathways that are related to colorectal cancer: one that involves endogenous estradiol, and a second pathway broadly associated with obesity, hyperinsulinemia, and free IGF-I.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18172327      PMCID: PMC4225702          DOI: 10.1158/0008-5472.CAN-07-2946

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency.

Authors:  A Juul; K Holm; K W Kastrup; S A Pedersen; K F Michaelsen; T Scheike; S Rasmussen; J Müller; N E Skakkebaek
Journal:  J Clin Endocrinol Metab       Date:  1997-08       Impact factor: 5.958

2.  A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women.

Authors:  Esther K Wei; Jing Ma; Michael N Pollak; Nader Rifai; Charles S Fuchs; Susan E Hankinson; Edward Giovannucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-04       Impact factor: 4.254

3.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.

Authors: 
Journal:  Control Clin Trials       Date:  1998-02

4.  Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study.

Authors:  Tetsuya Otani; Motoki Iwasaki; Shizuka Sasazuki; Manami Inoue; Shoichiro Tsugane
Journal:  Int J Cancer       Date:  2007-05-01       Impact factor: 7.396

5.  Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system.

Authors:  Y Nakayama; H Sakamoto; K Satoh; T Yamamoto
Journal:  Cancer Lett       Date:  2000-12-08       Impact factor: 8.679

6.  Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice.

Authors:  Nancy L Cho; Sara H Javid; Adelaide M Carothers; Mark Redston; Monica M Bertagnolli
Journal:  Cancer Res       Date:  2007-03-01       Impact factor: 12.701

7.  Downregulation of estrogen-metabolizing 17 beta-hydroxysteroid dehydrogenase type 2 expression correlates inversely with Ki67 proliferation marker in colon-cancer development.

Authors:  Olayiwola O Oduwole; Veli V Isomaa; Pasi A Nokelainen; Frej Stenbäck; Pirkko T Vihko
Journal:  Int J Cancer       Date:  2002-01-01       Impact factor: 7.396

8.  Association of markers of insulin and glucose control with subsequent colorectal cancer risk.

Authors:  Sharon H Saydah; Elizabeth A Platz; Nader Rifai; Michael N Pollak; Frederick L Brancati; Kathy J Helzlsouer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-05       Impact factor: 4.254

9.  Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men.

Authors:  N F Chu; D Spiegelman; N Rifai; G S Hotamisligil; E B Rimm
Journal:  Int J Obes Relat Metab Disord       Date:  2000-09

10.  Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition.

Authors:  Mazda Jenab; Elio Riboli; Rebecca J Cleveland; Teresa Norat; Sabina Rinaldi; Alexandra Nieters; Carine Biessy; Ann Tjønneland; Anja Olsen; Kim Overvad; Henning Grønbaek; Françoise Clavel-Chapelon; Marie-Christine Boutron-Ruault; Jakob Linseisen; Heiner Boeing; Tobias Pischon; Dimitrios Trichopoulos; Eleni Oikonomou; Antonia Trichopoulou; Salvatore Panico; Paolo Vineis; Franco Berrino; Rosario Tumino; Giovanna Masala; Petra H Peters; Carla H van Gils; H Bas Bueno-de-Mesquita; Marga C Ocké; Eiliv Lund; Michelle A Mendez; María José Tormo; Aurelio Barricarte; Carmen Martínez-García; Miren Dorronsoro; José Ramón Quirós; Göran Hallmans; Richard Palmqvist; Göran Berglund; Jonas Manjer; Timothy Key; Naomi E Allen; Sheila Bingham; Kay-Tee Khaw; Anne Cust; Rudolf Kaaks
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

View more
  112 in total

1.  Sex hormones and colorectal cancer: what have we learned so far?

Authors:  Jennifer H Lin; Edward Giovannucci
Journal:  J Natl Cancer Inst       Date:  2010-11-10       Impact factor: 13.506

2.  Genetic variation in insulin pathway genes and distal colorectal adenoma risk.

Authors:  A Joan Levine; Ugonna Ihenacho; Won Lee; Jane C Figueiredo; David J Vandenberg; Christopher K Edlund; Brian D Davis; Mariana C Stern; Robert W Haile
Journal:  Int J Colorectal Dis       Date:  2012-05-30       Impact factor: 2.571

3.  Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias?

Authors:  Sophie Morois; Agnès Fournier; Françoise Clavel-Chapelon; Sylvie Mesrine; Marie-Christine Boutron-Ruault
Journal:  Eur J Epidemiol       Date:  2012-05-29       Impact factor: 8.082

4.  Higher parity and earlier age at first birth are associated with lower risk of death from colon cancer.

Authors:  Chao-Hung Kuo; Chien-Chun Kuo; Hsiu-Yi Wu; Deng-Chyang Wu; Chun-Yuh Yang
Journal:  Cancer Sci       Date:  2012-07-04       Impact factor: 6.716

5.  The Frequency and Risk Factors of Colorectal Adenoma in Health-Check-up Subjects in South Korea: Relationship to Abdominal Obesity and Age.

Authors:  Ki-Seong Kim; Hong Ju Moon; Chang Hwan Choi; Eun Kyung Baek; Seung Young Lee; Bong Ki Cha; Hyun Woong Lee; Hyung Joon Kim; Jae Hyuk Do; Sae Kyung Chang
Journal:  Gut Liver       Date:  2010-03-25       Impact factor: 4.519

6.  Post Genome-Wide Gene-Environment Interaction Study Using Random Survival Forest: Insulin Resistance, Lifestyle Factors, and Colorectal Cancer Risk.

Authors:  Su Yon Jung; Jeanette C Papp; Eric M Sobel; Zuo-Feng Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2019-09-25

7.  The effects of genetic variants related to insulin metabolism pathways and the interactions with lifestyles on colorectal cancer risk.

Authors:  Su Yon Jung; Zuo-Feng Zhang
Journal:  Menopause       Date:  2019-07       Impact factor: 2.953

8.  Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells.

Authors:  Naveena B Janakiram; Altaf Mohammed; Misty Brewer; Taylor Bryant; Laura Biddick; Stan Lightfoot; Gopal Pathuri; Hariprasad Gali; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-15

9.  Associations of serum insulin-like growth factor-I and insulin-like growth factor-binding protein 3 levels with biomarker-calibrated protein, dairy product and milk intake in the Women's Health Initiative.

Authors:  Jeannette M Beasley; Marc J Gunter; Andrea Z LaCroix; Ross L Prentice; Marian L Neuhouser; Lesley F Tinker; Mara Z Vitolins; Howard D Strickler
Journal:  Br J Nutr       Date:  2013-10-07       Impact factor: 3.718

Review 10.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.